Appendix Figure S1 . PC3-B2, B3 cells exhibit higher bone metastatic potential then PC-T2, T3 cells. 2 Appendix Figure S2. H2S treatment rescues reduced p65 nuclear translocation by CTH knockdown. 3 Appendix Figure S3. Prostate orthotopic implantation of PC3 cells with reduced CTH expression decreases tumor growth and distant metastasis. 4 Appendix Figure S4. Tube formation assay by HUVEC cells co-culturing in conditional medium from PC3-B2 cells with CTH knockdown. Appendix Fig S1. PC3-B2, B3 cells exhibit higher bone metastatic potential then PC-T2, T3 cells. 1x10 6 PC3-T2, T3, B2, or B3 cells were orthotopically injected into mouse prostate for 15-20 days. (A-B) The mice weight (A) and the tumor volume (B) were compared. Data are presented as means ± SEM (n = 6-8 mice per group). Student's t-test was used for the statistical analysis (*P<0.05). (C) Images of the orthotopic xenograft tumors and paraaortic lymph nodes of mice orthotopically implanted with PC3-T2, T3, B2, or B3 cells. (D) Images show H&E staining of paraaortic lymph node sections. T: metastatic tumor cells (scale bar: 0.4mm). 3 Appendix Fig S2. H2S treatment rescues reduced p65 nuclear translocation by CTH knockdown. (A) PC3 cells transfected with control or CTH siRNA were serum-starved overnight and then treated with 10% FBS with or without NaHS (100μM) for 1hr. Subcellular localization of p65 was detected by immunocytochemistry. Nuclei were counterstained with DAPI. The representative images are shown. Scale bars: 10μM. (B) The percent of nuclear staining for p65 was scored by counting the positive-nuclear stained cells and the total number of cells quantified in random microscopic fields.
Cells were photographed 16 hours after seeding, and the number of nodes formed was counted and averaged. Data shown represent the means ± SD (n=3 biological replicates). ANOVA followed by Tukey's post-hoc test was used for the statistical analysis. (*P<0.05; **P<0.01). Representative photos are shown on the left panel. 
Mutagenesis primer sequences
p65-C38S-F TTCCGCTACAAGTCCGAGGG p65-C38S-R AAGGCGATGTTCAGGCACCC p65-sgRNAresist-F GGTGCAGAAAGAGGATATCGAGGTGTATTTCACG p65-sgRNAresist-R CGTGAAATACACCTCGATATCCTCTTTCTGCACC CTH-Q240E-F CGTTTCTTGGAAAACTCTCTT CTH-Q240E-R AAGAGAGTTTTCCAAGAAACG siRNA sequence CTH-1 GGAGCUGAUAUUUCUAUGU CTH-2 CCUGGUGUCUGUUAAUUGU RPS3 GCAUCAAGGUGAAGAUCAU sgRNA sequence p65 sgRNA GCTTGCGAAAAGGAGCCTCGGG pRFP-C-RS-shCTH sequence CTH GGCTTAGAGGATGAGGAAGACCTACTGGA Appendix
